Intellia Therapeutics (NTLA) — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Claim profile

NTLA · Stock Price

USD 13.71+5.59 (+68.84%)

Market Cap: $1.7B

Historical price data

Market Cap: $1.7BPipeline: 4 drugs (1 Phase 3)Patents: 13Founded: 2014Employees: 300-500HQ: Cambridge, United States

Sector Ranking#2 in CRISPR / Gene Editing

Overview

Intellia Therapeutics is a leader in translating Nobel Prize-winning CRISPR/Cas9 technology into transformative genomic medicines. The company's strategy leverages a dual-platform approach—in vivo and ex vivo editing—to advance a pipeline targeting rare genetic diseases like hereditary angioedema (HAE) and ATTR amyloidosis, with key programs in late-stage development. Backed by a strong intellectual property foundation and a strategic partnership with Regeneron, Intellia is building toward becoming a fully integrated, commercial-stage biopharmaceutical company.

Genetic DiseasesOncologyAutoimmune Conditions

Technology Platform

A dual CRISPR/Cas9-based genome editing platform featuring in vivo delivery via lipid nanoparticles (LNPs) for direct editing inside the body and ex vivo editing of cells like T cells and hematopoietic stem cells for reinfusion.

Pipeline

4

4 drugs in pipeline1 in Phase 3

Drug	Indication	Stage
NTLA-2002 + Normal Saline IV Administration	Hereditary Angioedema	Phase 3
Biological NTLA-3001	Lung Disease	Phase 1/2
Biological NTLA-2002	Hereditary Angioedema	Phase 1/2
NTLA-2001	Transthyretin-Related (ATTR) Familial Amyloid Polyneuropathy	Phase 1

Funding History

4

Total raised:$468M

Follow-on Offering$275MUndisclosedJun 15, 2021

IPO$108MUndisclosedMay 6, 2016

Series B$70MOrbiMedMay 15, 2015

Series A$15MAtlas VentureNov 15, 2014

Opportunities

The successful development of a one-time, potentially curative therapy for diseases like HAE and ATTR amyloidosis represents a multi-billion dollar market opportunity and could establish a new treatment paradigm.

Success with the in vivo LNP platform would also de-risk expansion into numerous other liver-targeted genetic diseases.

Risk Factors

Key risks include long-term safety uncertainties of in vivo CRISPR editing, regulatory hurdles for novel genomic medicines, intense competition from both gene editing and established RNA-targeted therapy companies, and the commercial challenges of launching ultra-high-cost, one-time therapies.

Competitive Landscape

Intellia faces competition from other CRISPR leaders like CRISPR Therapeutics and Editas Medicine, next-generation editing companies like Beam Therapeutics, and established players in its target diseases, such as Alnylam in ATTR amyloidosis and BioMarin/Takeda in HAE. Its differentiation lies in its clinically validated in vivo LNP delivery and the Regeneron partnership.